Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01771-0 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Ezgi Yalcin Gungoren und 16 weiteren Autor:innen. Beteiligte Einrichtung: Depatment of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Quality of Life, Immunoglobulins, Intravenous, Immunoglobulin G, Patient Satisfaction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marmara University.
Abstract (Originalsprache)
Background
Immunoglobulin G replacement therapy (IgRT), intravenous (IV) and subcutaneous (SC) routes, is pivotal in treatment of primary immunodeficiencies (PID). In recent years, facilitated subcutaneous immunoglobulin (fSCIG), a combination of rHuPH20 and 10% IgG has emerged as a delivery method to combine advantages of both IV and SC.
Method
In an observational prospective cohort, we investigated patient experience with fSCIG in PID patients from 5 PID centers for up to 12 months. We assessed the efficacy and safety of this treatment with patient/caregiver- and physician-reported indicators. Additionally, we analyzed patient treatment satisfaction (TSQM-9) and quality of life (QoL).
Results
We enrolled 29 patients (22 pediatric and 7 adults; 14 females and 15 males; (median: 15, min–max: 2–40.9 years) who initiated fSCIG as IgRT-naive (n = 1), switched from conventional rapid-push 10% SCIG (n = 6) or IVIG (n = 22). Among the participants, 19 (65%) exhibited antibody deficiencies, 8 (27%) combined immunodeficiencies, and 2 (7%) immune dysregulations. Remarkably, targeted trough immunoglobulin G levels were achieved under all previous IgRTs as well as fSCIG. No severe systemic adverse drug reactions were documented, despite prevalent local (%86.45) and mild systemic (%26.45) adverse reactions were noted with fSCIG. Due to mild systemic symptoms, 2 patients switched from fSCIG to 10% SCIG. The patient satisfaction survey revealed a notable increase at 2-4th (p = 0.102); 5-8th (p = 0.006) and 9-12th (p < 0.001) months compared to the baseline. No significant trends were observed in QoL surveys. Conclusion fSCIG demonstrates admissable tolerability and efficacy in managing PIDs in addition to notable increase of patients’ drug satisfaction with IgRT. The identified benefits support the continuation of this therapy despite the local reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Depatment of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey.
- Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
- The Isil Berat Barlan Center for Translational Medicine, Division of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
- Department of Pediatrics, Division of Allergy and Immunology, Sakarya University, Training and Research Hospital, Sakarya, Turkey.
- Depatment of Pediatrics, Division of Allergy and Immunology, Istanbul University- Cerrahpasa, Istanbul, Turkey.
- Department of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
Förderung
- Marmara University
Zitieren
APA
Yalcin Gungoren, E., Yorgun Altunbas, M., Dikici, U., Meric, Z., Eser Simsek, I., Kiykim, A., Can, S., Karabiber, E., Yakici, N., Orhan, F., Cokugras, H., Aydogan, M., Ozdemir, O., Bilgic Eltan, S., Baris, S., Ozen, A., & Karakoc-Aydiner, E. (2024). Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01771-0
Vancouver
Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, Meric Z, Eser Simsek I, Kiykim A, et al. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01771-0
BibTeX
@article{YalcinGungoren2024,
author = {Yalcin Gungoren, Ezgi and Yorgun Altunbas, Melek and Dikici, Ummugulsum and Meric, Zeynep and Eser Simsek, Isil and Kiykim, Ayca and Can, Salim and Karabiber, Esra and Yakici, Nalan and Orhan, Fazil and Cokugras, Haluk and Aydogan, Metin and Ozdemir, Oner and Bilgic Eltan, Sevgi and Baris, Safa and Ozen, Ahmet and Karakoc-Aydiner, Elif},
title = {Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01771-0}
}
EUVIMED